Drug Trial Radar · NCT01904409
Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis
Last checked: Nov 19, 2026Latest source record: Oct 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
420
Actual
Start
Jun 2013
Primary completion
Jun 2015
Study completion Jul 2015
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as all-cause mortality (death due to all causes) or hospitalization, in subjects with early decompensated liver cirrhosis. Rifaximin, a non-systemic antibacterial agent, is currently marketed as a 550 mg tablet for the reduction in risk of recurrent overt hepatic encephalopathy, a complication of liver cirrhosis. The rifaximin SSD tablet was formulated to maximize the efficacy of rifaximin. Subjects will receive 1 of 5 doses of rifaximin SSD tablets or placebo tablets every day for 24 weeks.
Conditions
- Liver Cirrhosis
Interventions
PlaceboDrug
Rifaximin SSD 40 mg IR tabletDrug
Rifaximin SSD 80 mg IR tabletDrug
Rifaximin SSD 40 mg SER tabletDrug
Rifaximin SSD 80 mg SER tabletDrug
Rifaximin SSD 80mgIR/80mgSER tabletDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to all-cause mortality or hospitalization that is attributable to complications of liver disease.Time frame: Weeks 1 through 24
Locations
120 sites in 2 countries. Site status is shown where the registry gives one.
Salix Investigative Site
Birmingham, Alabama
Salix Investigative Site
Dothan, Alabama
Salix Investigative Site
Mobile, Alabama
Salix Investigative Site
Tucson, Arizona
Salix Investigational Site
Artesia, California
Salix Investigational Site
Bakersfield, California
Salix Investigational Site
Chula Vista, California
Salix Investigational Site
Coronado, California
Salix Investigational Site
Costa Mesa, California
Salix Investigative Site
Fresno, California
Salix Investigational Site
La Jolla, California
Salix Investigative Site
Los Angeles, California
Salix Investigational Site
Monterey, California
Salix Investigational Site
Riverside, California
Salix Investigational Site
San Diego, California
Salix Investigational Site
Ventura, California
Salix Investigational Site
Englewood, Colorado
Salix Investigational Site
Littleton, Colorado
Salix Investigational Site
Bristol, Connecticut
Salix Investigational Site
New Haven, Connecticut
Salix Investigational Site
Waterbury, Connecticut
Salix Investigational Site
Coral Gables, Florida
Salix Investigational Site
Gainesville, Florida
Salix Investigative Site
Hialeah, Florida
Salix Investigational Site
Hialeah, Florida
Salix Investigational Site
Hollywood, Florida
Salix Investigative Site
Inverness, Florida
Salix Investigational Site
Lake Worth, Florida
Salix Investigative Site
Largo, Florida
Salix Investigative Site
Maitland, Florida
Salix Investigational Site
Miami, Florida
Salix Investigational Site
Miami, Florida
Salix Investigational Site
Miami, Florida
Salix Investigational Site
Miami Springs, Florida
Salix Investigational Site
New Port Richey, Florida
Salix Investigative Site
Orlando, Florida
Salix Investigational Site
Pembroke Pines, Florida
Salix Investigational Site
Port Orange, Florida
Salix Investigational Site
Saint Cloud, Florida
Salix Investigational Site
Tamarac, Florida
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.